Michael F. Driscoll
Expertise in
46
conditions

Dr. Michael F. Driscoll

Oncology
676 South Floyd Street, 
Louisville, KY 
On Staff At
Accepting New Patients
Offers Telehealth
21 Years of Experience
Expertise in
46
conditions
676 South Floyd Street, 
Louisville, KY 

Overview

Michael Driscoll is an Oncologist in Louisville, Kentucky. Dr. Driscoll has been practicing medicine for over 21 years is highly rated in 46 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lynch Syndrome. Dr. Driscoll is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Louisiana State University At Shreveport, Doctor Of Medicine, 2005

Residency

University of Louisville School of Medicine, Internal Medicine, 2008

Specialties

Oncology

Licenses

Internal Medicine in KY

Board Certifications

American Board Of Internal Medicine, Medical Oncology - 2011
American Board Of Internal Medicine, Internal Medicine - 2008

Fellowships

University of Louisville School of Medicine, Hematology, 2011

Hospital Affiliations

Norton Hospitals, Inc
UOFL HEALTH - JEWISH HOSPITAL And Mary & Elizabeth Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Ambetter
  • EPO
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MHS
  • EPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Norton Cancer Institute - Downtown
676 South Floyd Street, Louisville, KY 40202
Other Locations
Norton Cancer Institute - Audubon
2355 Poplar Level Road, Suite 405, Louisville, KY 40217

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
View 3 Less Clinical Trials

1 Total Publications

Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Journal: Annals of surgical oncology
Published: February 07, 2022
Similar Doctors
Expertise in
15
conditions
Dr. Jason Chesney
Oncology
Expertise in
15
conditions
Dr. Jason Chesney
Oncology

Uofl Health-Brown Cancer Center

529 S Jackson St, 
Louisville, KY 
 (2.5 miles away)
502-562-4673
Languages Spoken:
English
See accepted insurances

Jason Chesney is an Oncologist in Louisville, Kentucky. Dr. Chesney is highly rated in 15 conditions, according to our data. His top areas of expertise are Melanoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma.

Expertise in
16
conditions
Dr. Renato La Rocca
Oncology
Expertise in
16
conditions
Dr. Renato La Rocca
Oncology

Norton Healthcare Pavilion

315 E Broadway, 
Louisville, KY 
 (2.5 miles away)
502-629-2500
Languages Spoken:
English
See accepted insurances

Renato La Rocca is an Oncologist in Louisville, Kentucky. Dr. La Rocca is highly rated in 16 conditions, according to our data. His top areas of expertise are Astrocytoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT).

Expertise in
15
conditions
Dr. Arash Kalebasty
Oncology
Expertise in
15
conditions
Dr. Arash Kalebasty
Oncology

Norton Cancer Institute-Clark

301 Gordon Gutmann Blvd Ste 301, 
Jeffersonville, IN 
 (8.2 miles away)
502-629-2500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arash Kalebasty is an Oncologist in Jeffersonville, Indiana. Dr. Kalebasty is highly rated in 15 conditions, according to our data. His top areas of expertise are Familial Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy.

Frequently Asked Questions about Dr. Michael F. Driscoll

How do I make an appointment with Dr. Michael F. Driscoll?

You can book an appointment with Dr. Michael F. Driscoll by calling their office at 502-629-2500. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael F. Driscoll a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael F. Driscoll is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael F. Driscoll specialize in?

While Dr. Michael F. Driscoll is a Oncology, they have specific expertise in Colorectal Cancer, Familial Colorectal Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Michael F. Driscoll participate in research or clinical trials?

Yes. Dr. Michael F. Driscoll has published 1 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Michael F. Driscoll's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael F. Driscoll accept my insurance?

Dr. Michael F. Driscoll accepts most major insurance plans, including Aetna and Ambetter. We recommend calling the office directly at 502-629-2500 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Driscoll's expertise for a condition
ConditionClose
    View All 20 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 66 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile